Dry eyes with Meibomian gland dysfunction
Conditions
Interventions
Experimental group:Herba houttuynia drops eye drops
Control group:Houttuynia houttuynia eye drops analog agent
Sponsors
Xiamen Eye Center Affiliated to Xiamen University/China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) sign informed consent; (2) patients with dry eyes and tarsal gland dysfunction; (3) patients with mild to moderate dry eyes, i.e.; (4) aged 18-70 years; (5) not using or disusing artificial tears for more than 7 days.
Exclusion criteria
Exclusion criteria: (1) suffering from other eye diseases, such as macular degeneration, glaucoma, keratitis and retinal vascular embolism; (2) patients with lacrimal duct obstruction, prominent eyeball protrusion and severe corneal decompensation; (3) fluorescein staining is greater than or equal to 10 staining points; (4) less than half a year of eye surgery; (5) those who had a history of wearing corneal contact lens within one week before admission; (6) suffering from serious primary diseases such as cardiovascular and cerebrovascular, liver, kidney and hematopoietic system; (7) those with allergic constitution and those who are allergic to the test drug ingredients; (8) those who have participated in other clinical trials in the past 3 months; (9) patients who are unable to cooperate or have mental illness should not participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total eye symptom score and single symptom score;Tear rupture time;Schirmer I test;Palpebral margin change score;Blepharoplasty score;Palpebral gland secretion score;Tarsal gland deficiency score;Conjunctival congestion score;Fluorescein staining score;Naked eyes and corrected vision;Evaluation of eye tolerance and irritant symptoms;Evaluation of treatment satisfaction; | — |
Countries
China
Contacts
Public ContactLiu ZuguoJin Ming
China-Japan Friendship Hospital
Outcome results
None listed